Capricor Therapeutics Inc. shares have been trading down by -51.54 percent amid heightened concern over its latest clinical trial outlook.
Click Here for a Millionaire's POV on Trading CAPR
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways For CAPR Traders
- FDA advisory committee briefing documents for Capricor’s lead cell therapy deramiocel questioned the effectiveness data, statistical methodology, and overall benefit–risk profile, including a post‑hoc change in the primary endpoint analysis.
- Following release of the FDA staff’s highly critical briefing materials, Capricor’s shares plunged roughly 60–70%, trading around $7.00 at one point and suffering an intraday decline of about 62–65%.
- Multiple plaintiffs’ law firms, including Kehoe Law Firm, Block & Leviton, Rosen Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith, have launched or announced investigations into potential securities fraud or investor claims related to Capricor’s prior statements about deramiocel’s efficacy data and regulatory review.
- An analyst from Cantor Fitzgerald characterized the FDA briefing documents on deramiocel as painting an “ugly picture” and raising questions about data integrity, adding to regulatory and litigation concerns around Capricor.
Live Update At 08:33:51 EDT: On Thursday, July 30, 2026 Capricor Therapeutics Inc. stock [NASDAQ: CAPR] is trending down by -51.54%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Capricor Therapeutics Inc. just showed traders what a full‑blown repricing looks like. CAPR closed near $19.70–$19.80 in late July, then collapsed into the mid‑single digits once the FDA briefing documents hit. The daily chart goes from a tight high‑teens range to a straight‑down move, with CAPR printing around $6.57 after the dust started to settle.
The intraday tape backs up the shock. In premarket five‑minute candles, CAPR traded as low as the mid‑$2s before bouncing toward $3. That kind of 70% gap‑down followed by wild premarket swings tells you one thing: forced selling and panic.
More Breaking News
- SOFI Stock Slides Off Highs As Momentum Traders Reassess
- GMM Stock Wobbles As Heavy AI Spending Fuels Big Loss
- Sandisk (SNDK) Whipsaws As AI Hype And WSB Traders Collide
- NU Stock Holds Gains As Price Action Tightens
On the fundamentals, the filings show Capricor running a classic high‑burn biotech profile. The company reported a quarterly net loss, negative operating cash flow, and negative free cash flow, while key profitability ratios like pretax margin and returns on equity and assets are deeply in the red. At the same time, CAPR’s balance sheet carries a low debt‑to‑equity ratio and a very high current ratio, meaning liquidity is strong enough for now. For traders, that combination usually means one clear focus: the binary outcome around the lead drug, because the business itself is not funding the story.
Why Traders Are Watching CAPR After The FDA Shock
CAPR is now a live case study in how fast sentiment can flip when a single asset drives the whole story. The FDA advisory committee briefing documents on deramiocel did more than nitpick; they questioned whether the HOPE‑2 and HOPE‑3 data provide substantial evidence of effectiveness in Duchenne‑related cardiomyopathy and flagged an unfavorable benefit–risk profile. Once those concerns, including post‑hoc changes to the primary endpoint and statistical plan, hit the tape, traders wasted no time hitting the sell button.
Capricor Therapeutics saw roughly 60–70% of its market value erased in a blink, with CAPR changing hands near $7.00 and even lower in fast markets. The link is direct: FDA staff questioned data handling, methodology, and safety signals such as hypersensitivity and anaphylaxis, and the stock fell about 62–65% intraday on heavy volume. That is the market repricing the probability that deramiocel ever becomes a commercial product.
Wall Street commentary lined up with the regulators. An analyst at Cantor Fitzgerald said the FDA documents painted an “ugly picture” and raised data‑integrity questions. Meanwhile, multiple firms downgraded CAPR to Neutral and aggressively slashed price targets, signaling that the Street now sees approval in the current form as unlikely.
Then comes the legal overhang. Kehoe Law Firm, Block & Leviton, Rosen Law Firm, Levi & Korsinsky, and the Law Offices of Howard G. Smith have all announced securities‑fraud or shareholder‑rights investigations tied to deramiocel disclosures and the subsequent plunge in CAPR. For short‑term trading, that means recurring headline risk, possible class‑action filings, and a management team that may be spending more time with lawyers than on strategic pivots. CAPR has gone from a high‑beta biotech play to a deeply damaged story that will likely trade on every new FDA or legal headline.
Conclusion
For active traders, CAPR is now in the “broken story” category. The FDA advisory panel briefing documents and a later 9–3 vote that deramiocel’s benefits do not outweigh its risks sharply reduce near‑term approval odds. When CAPR drops from nearly $20 to the mid‑single digits on those headlines, the chart is telling you the market no longer believes the old narrative around deramiocel.
Capricor Therapeutics still has cash and a relatively clean balance sheet, but the income statement and cash‑flow data show a company dependent on external funding and future drug success, not operating profits. With CAPR facing both regulatory pushback and a growing swarm of securities‑law investigations, dilution and restructuring risk move higher on every timeframe traders care about.
That does not mean CAPR stops moving. In this kind of high‑volatility, low‑trust environment, sharp dead‑cat bounces and painful short squeezes are common. These kinds of moves can tempt even experienced traders to chase spikes and abandon discipline. As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.” But they are trading setups, not safety nets. As Tim Sykes likes to remind his students, “Volatility is opportunity, but only if you respect the risk and cut losses quickly.” For anyone watching CAPR now, the homework is simple: track every FDA and court update, understand that deramiocel is no longer a clean catalyst, and treat every bounce as a trade, not a promise. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.